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DYRK1A is one of five members of the Dual-specificity tyrosine (Y) phosphorylation-Regulated 
Kinase (DYRK) family. The DYRK1A gene is located in the Down syndrome critical region and 
regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells 
during early development. This has focused research on to its role in neuronal degenerative 
diseases, including Alzheimer’s and Down syndrome; recent studies have also shown a possible 
role of DYRK1A in diabetes. Here we report a variety of scaffolds not generally known for 
DYRK1A inhibition, demonstrating their effects in in vitro assays and also in cell cultures. These 
inhibitors effectively block the tau phosphorylation that is a hallmark of Alzheimer’s Disease. 
The crystal structures of these inhibitors support the design of optimized and novel therapeutics. 
 
INTRODUCTION 
Alzheimer’s disease (AD) is the primary cause of dementia in the elderly1. AD affects less than 
5% of individuals 65 years of age and younger, but the incidence of AD reaches nearly 40% in 
patients 85 years of age and older1.  This neurodegenerative disorder is characterized by neuronal 
death and loss of gray matter in the frontal cortex and hippocampus. This neurodegenerative 
disorder is characterized by neuronal death and loss of gray matter in the frontal cortex and 
hippocampus. Memory loss is a typical symptom of AD and has been linked to the accumulation 
of amyloid plaques and neurofibrillary tangles (NFTs)2. The latter process is mediated by 
hyperphosphorylation of tau proteins that are inactive and form multiple aggregates. According to 
the β−amyloid cascade hypothesis, the deposition of insoluble β-amyloid is responsible for 
neuronal death. Plaques are constituted by β-amyloid peptides (Aβ) that are generated via the 
cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Aβ-fragments, 37-42 
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amino acids in length, may produce soluble oligomers, although they aggregate into insoluble 
β-amyloid plaques in AD2, 3. Alternatively, the insoluble hyperphosphorylated tau proteins and 
the buildup of NFTs may be the etiology of neuronal death4-6. Both mechanisms of neuronal 
pathology depend on the kinase DYRK1A, which regulates the cell cycle, neuronal 
differentiation and synaptic transmission7. 
Increased levels of DYRK1A are present in the brain of patients with AD and in other 
neurodegenerative diseases, including Parkinson, Huntington and Pick syndromes7. The human 
DYRK1A gene is located in the Down syndrome critical region (DSCR) encoded by chromosome 
21, and the overexpression of DYRK1A likely contributes to the neurological abnormalities of 
this  disorder8. 
DYRK1A increases the secretase-mediated cleavage of APP into Aβ peptides. DYRK1A 
phosphorylates APP directly9 and the Aβ peptides stimulate DYRK1A expression in a positive 
feedback loop9. Additionally DYRK1A phosphorylates presenilin 1 (PSEN1)10, one of the four 
core proteins in the γ-secretase complex, which enhances secretase activity. DYRK1A 
phosphorylates human microtubule associated protein tau at eleven different sites11, whereby 
most of the tau protein becomes hyperphosphorylated. The initial phosphorylation of tau by 
DYRK1A triggers tau phosphorylation by GSK3β, which potentiates self-aggregation and fibril 
formation in vitro11, 12. Because of the central role of DYRK1A in the development and 
progression of AD, DYRK1A has emerged as a high priority target for inhibition, offering a 
novel approach for the treatment of AD. In recent years, evidence has built up that point to a role 
of DYRK1A in diabetes and β-cell proliferation13-15, expanding the pharmaceutical application of 
a DYRK1A inhibitor. Therefore, we screened a diverse set of scaffolds for their ability to inhibit 
DYRK1A kinase activity and to prevent tau phosphorylation. The diversity of the novel scaffolds 
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and the binding modes determined by crystal structure and in vitro assays may lead to the 
development of novel strategies for the clinical treatment of AD. 
 
RESULTS 
Identification of novel DYRK1A inhibitors 
Novel DYRK1A inhibitors were identified by employing KinomeScanTM screening data of an 
in-house library of approximately 1,000 compounds including previously synthesized kinase 
inhibitors.  23 compounds were chosen as candidates for activity assay and their ability to inhibit 
the phosphorylation of DYRKtide (RRRFRPASPLRGPPK) by DYRK1A at a fixed 
concentration of 20 µM with an ATP regenerative assay (Cook et al.16). The results for the most 
promising compounds are shown in Table 1 and all the 23 compounds are shown in the 
supporting information Table S1. The inhibitors had a broad range of activity: 8 compounds 
showed strong inhibition (remaining activity <5%), 8 compounds showed moderate inhibition 
(11%-46% remaining activity) and 6 compounds showed little or no inhibition (70%-100% 
remaining activity). 15 inhibitors that showed at least 50% inhibition were titrated in decreasing 
concentrations (200µM-20nM) to determine the IC50 and Ki values.  
 
Compounds AC12, AC13, AC14, AC15 and AC27 were found to possess highest ability to 
inhibit the phosphorylation of DYRKtide, with Ki values around 100-250 nM. AC7, AC24 and 
AC25 inhibitors showed Ki values of around 326 nM - 570 nM. Inhibitors with identical core 
scaffolds revealed similar Ki values, as seen for the two pairs AC12 and AC15 (~104 nM and 
~158 nM), and AC24 and AC25 (383 nM and 575 nM, respectively). The remaining compounds 
(AC2, AC8, AC16, AC18, AC20, AC22, and AC23) were weaker compared to the 8 inhibitors 
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discussed above and exhibited Ki values ranging from 1.7 µM to >8 µM (supporting information 
Table S1).  


























AC22 XMD8-49 24 >6000 >2800 0.7 -  active 5-10 µM 6EIL 
AC23 XMD8-62e 15 4200 2015 1.6 -  active 0.5-1 µM 6EIP 
AC20 HG-8-60-1 11 3500 1680 1.2 - active >20 µM 6EIJ 
AC25 XMD15-27 4 1200 575 0.15 - active † 6EIR 
AC24 XMD14-124 1.3 800 383 0.05 - active 10-20 µM 6EIQ 
AC27 JWC-055 2 532 252 - 1.4 active 0.05-0.1 µM 6EIS 
AC15 XMD7-112 0 329 158 ** - active 5-10 µM 6EJ4 
AC12 XMD7-117 0 216 104 ** - active 1-5 µM 6EIF 
AC28 JWD-065* - - -  0 - - - 6EIV 
 
IC50 values determined in the Cook assay at 25 degrees and 128 µM ATP, Ki calculated with a 
KM value for DYRK1A of 118 µM
17. *due to solubility problems of the compound in stock 
solution and resulting uncertainty of the concentration, binding kinetics were not measured, 
however a cocrystal structure with inhibitor could be obtained. **values available for DYRK1B 
only (0.5 and 0.2 respectively). *** Concentration where inhibitory activity was above 1.5 fold 
the basal level. †compound failed to inhibit DYRK1A in this assay, negatively interferes with the 
cells.  
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Figure 1. Structures of the nine novel DYRK1A inhibitors, representing six different core 
scaffolds. AC12 and AC15 share one core structure, and AC24, AC25 and AC28 share a second 







Tau phosphorylation inhibitory activity assay in cells 
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Eight compounds that displayed inhibitory activity in vitro (see Table 1) were further tested in 
a cell line to establish whether they possessed the capacity to inhibit tau phosphorylation by 
DYRK1A. Expression vectors encoding FLAG-tagged TAU and EGFP-tagged DYRK1A were 
co-transfected into NCI-H1299 cells and the amount of phospho-tau protein (p-tau) was analyzed 
by Western blot (Figure 2 and supporting information Figure S2). Cells transfected with empty 




Figure 2. Inhibition of DYRK1A dependent tau T212 phosphorylation by different compounds. 
NCI-H1299 cells were transfected with expression vector encoding FLAG-tagged tau in 
combination with either empty expression vector or EGFP-tagged DYRK1A. Twenty hours after 
transfection the cells were incubated for 2 hours with vehicle (-) or the indicated inhibitor 
concentration before the cells were harvested. Phosphorylated T212 tau was detected by Western-
blotting using the polyclonal anti-phospho T212 tau antibody (44-740G, Invitrogen), total FLAG- 
tau was detected by using a monoclonal M2 anti-FLAG antibody (F1804, Sigma-Aldrich) and 
EGFP-DYRK1A by a polyclonal anti-GFP antibody (Sc-8334, Santa-Cruz). 
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AC12, AC15, AC24 and AC25 showed a significant dose-dependent inhibition of pT212-tau 
phosphorylation, in contrast to AC20, AC22, AC23 and AC27. However, all these compounds 
inhibited pT212-tau phosphorylation. The degree of kinase inhibition observed at the protein 
level reflected the one seen in the in vitro activity assay. In general, compounds with Ki of 
600 nM or tighter showed clear dose-response effects, while compounds with Ki values ranging 
from 1.7 to 3 µM showed inhibition but with significantly greater noise with respect to dose-
response correlation. An exception to this general observation is AC27. This compound inhibits 
DYRK1A in the pT212-tau phosphorylation assay, however not as potently as it would have been 
expected from the in vitro activity assay. 
 
Crystal structures 
The inhibitors were set up in co-crystallization trials with DYRK1A. Nine of the novel 
scaffolds (Figure 1) formed co-crystals. The crystal packing and asymmetric unit is similar to the 
previously published DYRK1A complexes with PKC41217 or the benzothiazole fragments18, with 
tetramers constituting the asymmetric unit. In general, the best electron density fit is found for 
protomer A and the greatest disorder is seen in protomer C. Several chains in the asymmetric unit 
show disulfide bridge formation between the HCD motif and the activation loop cysteine. 
However, in many chains the cysteine residues are reduced and/or in a mixed state, with 
additional evidence of radiation damage due to low amplitude electron density for cysteine 
C31217, 18. The compounds are bound to all four protomers in the tetramer of the asymmetric unit 
in DYRK1A (Figure 3). One exception is compound AC22, which lacks electron density for the 
entire inhibitor in chain C of the tetramer and the ATP-pocket is empty. However, the electron 
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density is clear for the other three chains. The omit difference density maps after simulated 
annealing for all the nine inhibitors are shown in the supporting information Figure S3. The 
crystallographic data and refinement statistics are summarized in supporting information Table 
S2 in the supplementary data.  
 
Figure 3. Binding pocket of DYRK1A bound to nine different inhibitors. The electron density 
for the inhibitor (2Fo-Fc map) is shown at 1 σ.  The inhibitors form hydrogen bonds to E239 and 
L241, and AC20, AC22 and AC27 form an H-bond to K188. Inhibitors AC12 and AC15 have a 
hydrogen bond acceptor group oriented toward K188. Most of inhibitors are shown as they bind 
to chain A of the four protein molecules in the asymmetric unit of DYRK1A. The two exceptions 
are AC23 where the inhibitor is shown bound in chain B, and AC27 with the inhibitor shown in 
chain D. In the AC23 crystal structure, only chain B has a water clearly visible in the electron 
density that could form bridging H-bonds between the inhibitor and K188 or D307. In the AC27 
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crystal structure chain D has a water molecule, which connects the inhibitor to the hinge. There is 
no clear electron density for a water in the other chains, however, some diffuse electron density 
might suggest water molecules at these positions, in the other chains too. PDB codes for 
DYRK1A complexes: AC12: 6EIF; AC15: 6EJ4; AC20: 6EIJ; AC22: 6EIL; AC23: 6EIP; 
AC24: 6EIQ; AC25: 6EIR; AC27: 6EIS; AC28: 6EIV. 
 
The inhibitors that could be co-crystallized with DYRK1A represent six different chemical 
scaffolds. Inhibitors AC12 and AC15 share a 3-(3-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-5-
yl)phenyl core scaffold, while inhibitors AC24, AC25 and AC28 share a 4-[4-amino-2-[2-
methoxy-4-(4-methylpiperazin-1-yl)anilino]-1,3-thiazole-5-carbonyl]phenyl core scaffold. AC12 
and AC15 differ by the substitutions of sulfonamide (para) or amine (meta) on the terminal arene, 
respectively. Compound AC24 represents the core scaffold, whereby compounds AC25 and 
AC28 have terminal acrylamide functions added to the terminal arene at para and meta positions, 
respectively. AC28 differs additionally by the lack of a methoxy substitution on the central 
phenyl ring. The other core scaffolds are represented by compounds AC20 with 7-azathiazole, 
AC22 as a pyrazine, AC23 with an alkaloid, and AC27 as a substituted 1,6-phenanthroline.  
With one exception, the inhibitors are typical hinge binders (Figure 3 and supporting 
information Figures S3, S4 and S5). AC12 and AC15 each make two hydrogen bonds to E239 
(gatekeeper+1) and L241 (gatekeeper+3). The pyridine nitrogen faces the catalytic lysine K188, 
but the 4 Å distance to the amine nitrogen is too long for a hydrogen bond. AC22 is anchored to 
the hinge via two hydrogen bonds, which orients the pyridine nitrogen H-bond acceptor towards 
the catalytic lysine K188. Compared to AC12 and AC15, the distances to K188 are shorter, 
including one contact at 3.2 Å, within the range of typical hydrogen bond distances. The crystal 
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structure also shows that K188 shares a salt bridge with E203. Similarly, the aminopyrimidine 
functionality of AC23 is anchored to the hinge, which points the benzamide substituent towards 
K188, but without a direct hydrogen bond interaction. However, in chain B there is a water 
molecule that bridges the gap between the amide and K188. The benzamide moiety has a parallel 
displaced π-π stacking interaction with the gatekeeper phenylalanine F238.  
AC24, AC25 and AC28 make three hydrogen bonds to the hinge via the thiazole and two 
adjoining amines. In addition, the piperazine rings of these compounds have salt bridge 
interactions with D247 (the gatekeeper+8 residue). They do not interact with K188. Compared to 
AC24, the addition of an acrylamide group on AC25 weakens binding, and the crystal structure 
shows no favorable interactions, and especially no covalent binding. A superposition of AC24, 
AC25, and AC28 from all asymmetric unit domains show that the acrylamide groups are pushed 
out of the binding pocket (Figure 4). However, the electron density for the acrylamide groups are 
relatively weak, and some divergence in their positions is evident in the refined structures. A 
rotation of the terminal benzene ring of approximately 90 degrees may be seen in two binding 
poses for AC25. The other benzene ring of the scaffold (adjacent to the piperazine ring) is 
oriented differently and heterogeneously for AC28. The methoxy substituent of this ring, found 
in AC24 and AC25, apparently stabilizes this benzene ring compared to AC28 (Figure 4). On 
the other hand, the ring of inhibitor AC28 is stabilized by intramolecular π-π interactions of the 
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Figure 4. Superposition of the binding pockets and inhibitors of the four chains in the 
asymmetric unit of DYRK1A of each inhibitor:  AC24 (green PDB: 6EIQ) with AC25 (cyan 
PDB: 6EIR) and AC28 (violet PDB: 6EIV). Although the general pose of each inhibitor remains 
similar, some differences are evident between the individual pockets. AC24 has the greatest 
conservation of geometry, while especially the acrylamide groups of AC25 and AC28 show more 
variation, reflected also by lower electron density for these parts.   
 
AC20 has only a single hinge binding hydrogen bond, with L241 (gatekeeper+3), rather than a 
pair (including the gatekeeper+1 residue E239) that is typical for the other inhibitors.  AC20 
shares a hydrogen bond with the catalytic lysine K188 with its urea oxygen, and also shares a salt 
bridge with the DFG aspartate D307 via the morpholine nitrogen. It forms in addition a 
perpendicular π stacking interaction with the gatekeeper phenylalanine. Like all the other 
inhibitors, AC20 binds in a typical type I binding mode. 
The strongest of the inhibitors in this study, AC27 uniquely has no hydrogen bond to the hinge. 
It has anchoring hydrogen bonds with K188 and E203 via its diazole group, with N244 via its 
carbonyl group, and also with the N292 side chain as a C-H--O hydrogen bond with a hydrogen 
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of the fluorinated arene. Additionally, a bridging water between the hinge and the inhibitor was 
found in the chain D of the tetramer. This water has a hydrogen bonding distance of 2.7 Å from 
the 1,6-phenanthroline nitrogen, and is in contact with the main chain amide nitrogen of L241 
with a distance of 2.8 Å and to the carbonyl of E239 of 2.6 Å. The trifluoromethyl, fluorobenzyl 
ring is in perpendicular face-edge intramolecular contact with both the 1,6-phenanthroline and 
diazole rings. The trifluoromethyl group is embedded in a shallow hydrophobic pocket created by 
the first glycine (G166) of the glycine rich loop, the preceding I165 side chain, and the V173 side 
chain opposite of G166. (Figure 3) A superposition of all the inhibitors is shown in supporting 
information Figure S4.  
 
Kinase profiling of DYRK1A inhibitors  
 We evaluated kinase selectivity profiles as determined by KinomeScanTM binding assays 
against a panel of 353/402/442 distinct kinases and their mutants (Figure 5). The kinase profiling 
data for the inhibitors show that AC12 and AC15 are pan kinase inhibitors (with a broad 
spectrum of inhibition). As a consequence, these two inhibitors did not show a clear pattern of 
selectivity, and were generally less effective against tyrosine kinases. The kinase profiling data 
for remaining seven of the compounds with cocrystal structures showed the typical cross 
reactivities of the inhibitors between DYRK and CLK families. In addition, AC22 and AC27 
show significant cross reactivities against GSK3β, which is consistent with the kinase selectivity 
pattern of leucettine L4119 
AC20 exhibited good overall kinome selectivity, with a S(10) selectivity score of 0.06 at 10 
µM. (The S(10) selectivity index is defined as the percentage of the kinome inhibited below 10% 
of the control; S[10] = [number of kinases with %Ctrl < 10]/[number of kinases tested]). AC20 
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binds CLK2 more tightly than DYRK1A. This compound bound also the tyrosine kinases ABL 
and PDGFR, which is unsurprising, considering that the series of compounds with this core 
structure were initially designed for targeting BCR-ABL20.  
AC22 is the only tested inhibitor that shows a stronger inhibition of GSK3β compared to 
DYRK1A. Other kinases of the CMGC group significantly inhibited by AC22 include CLK2, 
HIPK1/2 and CDK7. AC22 also interferes with other kinases across several families, albeit with 
weaker binding affinity. 
AC23 exhibited rather weak and unspecific DYRK binding. The main targets of this compound 
belonged to the CMGC and CAMK families, with DRAK1/2 and ERK5 as the top hits.  
The three thiazole compounds, AC24, AC25 and AC28, have slightly varying affinities. While 
AC24 had greater affinity for DYRKs compared to CLKs, the addition of the acrylamide in 
AC25 and AC28 shifted the profile towards CLK2, and also decreases the overall selectivity.  
AC27, an analog of mTOR inhibitor Torin221, selectively binds to mTOR, but also CMGC 
family kinases and lipid kinases PIK3CG, PIK4CB, with S(10) scores of 0.03 at 1 µM. It 
possesses similar inhibition strengths against DYRK1A/B, CLK1/3 and GSK3A/B among 
CMGC family members. 
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Figure 5 Kinome binding plots for the nine compounds. The levels of binding were measured at 
concentrations 10 µM (except for AC27, measured at 1 µM).  
 
NFAT Luc reporter assays 
The newly identified compounds were studied in the HEK293 cell line by introducing the 
NFAT luciferase activity assay (Figure 6). The compounds were titrated in increasing amounts 
from 0.25 µM to 20 µM. AC27, as the most active compound, was titrated from 0.05 µM to 
10 µM. With the exception of AC25, all compounds showed activity in the tested cell line. AC12 
was found to be active at concentrations up to 5 µM; higher concentrations of this compound led 
to a drop in the activity, suggesting that AC12 might be toxic at concentrations >5 µM.  AC15, 
despite sharing the same core structure of AC12, showed dose-dependent inhibition up to 20 µM; 
this compound required a minimum of 5 µM to show considerable activity above the background 
level. This was also the case for AC20, AC22 and AC24. Based on the NFAT luciferase activity 
assay, the most active compounds were AC23 and AC27. Specifically, AC27 showed clear 
activity at 50 nM and thus is approximately 10-fold more active than AC23 and approximately 
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100-fold more active than to the other six inhibitors in this assay. The drop in the activity of 
AC27 at 10 µM and AC23 at 20 µM may suggest that these concentrations might be toxic. As 
mentioned above, AC25 was the only inactive compound with respect to this assay, showing an 




Figure 6. NFAT Luc reporter assay. The plot is normalized to the basal activity of the luciferase. 
Numbers indicate the fold of increase in luciferase activity upon inhibition of DYRK1A (A). The 
most active compound AC27 shows a 1.5fold increase in luciferase activity at 50 nM. For 
comparison harmine is included in the same assay (B). Even though harmine reached a higher 
activity and does not display the drop in activity as AC27 at higher concentrations toward 
DYRK1A, AC27 is active at much lower concentrations. 100 nM AC27 leads to the same 
activity as 5 µM harmine, making AC27 nearly 50 times more active than harmine in this 
particular cellular assay. 
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The list of potential DYRK1A inhibitors has been growing over the past few years. Diverse 
chemical fragments that bind to DYRK1A with high affinity have been reported22. However, 
none of these have advanced into clinical trials. This study presents a set of novel scaffolds with 
good potential for DYRK1A inhibition, evaluated using a series of structural and cellular assay 
experiments. AC12, AC15 and AC22 are compounds with relatively low molecular weights and 
can considered as fragments and classical hinge binders. In contrast to harmine, INDY23 or  
recently published hydroxy- and methoxy-benzothiazole18 fragments, the distances of inhibitor 
atoms to the catalytic lysine or the aspartate from the DFG motive remain relatively long. On the 
other hand, structural variations in the physiological environment might include significant 
dynamic hydrogen bonding to the catalytic lysine K188, especially correlated with dynamic 
properties of helix C. Although AC12, AC15 and AC22 have similar molecular weights and 
similar binding poses with the hinge region, their binding strengths differ greatly. AC12 and 
AC15 were the strongest binders, while AC22 was one of the weakest that still enabled cocrystal 
structure determination. (The relatively weak binding of AC22 is also reflected in the fact that 
one of the ATP pockets of the four DYRK1A chains in the asymmetric unit of the crystal 
structure was empty). Detailed comparison of the structures AC12, AC15 and AC22 shows that 
the pyridine rings occupy the same volume, and the overlap of the nitrogen atoms anchored to the 
hinge is apparent (Figure 7A). However, the methoxy group of AC22 on the aniline ring most 
likely weakens the binding. The structure shows that the methoxy group pushes the compound 
away from the hinge, hence increasing intramolecular strain.  
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Figure 7. Orientation and interaction of the inhibitors in the binding pocket. (A) Superimposition 
of AC12 (cyan PDB: 6EIF) AC15 (pink PDB: 6EJ4) and AC22 (green PDB: 6EIL). The 
methoxy group of AC22 displaces the inhibitor away from the hinge, weakening binding. (B) 
Superposition of AC20 (green PDB: 6EIJ) with 5-hydroxy-benzothiazole (blue PDB: 5A3X) and 
6-cyano-benzothiazole (magenta PDB: 5A4T). AC20 binds with its 5-substiuted pyridothiazole 
in the same orientation as the 6-cyano-benzothiazole and, unlike 5-hydroxy-benzothiazole or 
INDY, does not make sulfur aromatic ring interactions with the gatekeeper phenylalanine. The 
three compounds also have differing selectivity profiles. While AC12 and AC15 are more nearly 
pan kinome inhibitors (targeting many different kinases), AC22 is much more discriminating, 
with however a greatly reduced inhibitory strength.  
 
The remaining inhibitors for which a cocrystal structure could be obtained are selective towards 
the CMGC kinase group and DYRKs. However, all show additional cross reactivity against 
targets outside the CMGC group. 
Inhibitor AC20 inhibits DYRK1A, however the strongest inhibition of CMGC group kinases is 
of CLK2, and similar or stronger inhibition is seen of TK group members ABL and PDGFRB 
(with considerable variation across ABL mutants).  AC20 is clearly hydrogen bonded to K188, 
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wrapping its extended tail across and partially around the DFG motif. The pyridothiazole core 
structure of AC20 is similar to the benzothiazoles found in other published DYRK1A inhibitors 
(including INDY23, BINDY24, or the recently published 5- or 6- substituted benzothiazole 
fragments18 ), but differs by an additional nitrogen in the six membered ring. AC20 is a 6-
substituted pyridothiazole; analogous to the benzothiazole interactions , the pyridothiazole binds 
alongside the hinge instead of making sulfur aromatic ring interactions with the gatekeeper as 
seen for INDY23 or the 5-substituted fragments of benzothiazoles18 (Figure 7B).   
The three thiazole compounds AC24, AC25 and AC28 show intermediate binding strengths 
and selectivity. Compound AC24 represents the core scaffold in this group, whereby compounds 
AC25 and AC28 have terminal acrylamide functions added to the terminal arene at para and meta 
positions, respectively. The addition of the acrylamide in AC25 and AC28 shifted the binding 
affinity away from DYRK towards CLK2, and also decreases the overall selectivity. Acrylamides 
as functional groups are typically used to introduce covalent binding of inhibitors via addition to 
cysteines. (These compounds were previously synthesized as inhibitors of kinases other than 
DYRK1A) Because of the absence of cysteine at the ATP pocket in DYRK1A, the acrylamides 
in AC25 and AC28 are not expected to introduce covalent binding, but nonbonded interactions 
still affect binding strengths. The functional acrylamide group might stabilize binding to related 
off-targets. AC25 was the only compound that did not inhibit DYRK1A in the NFATluc assay, 
instead showing toxicity.  
As described above, the crystal structure of AC25 showed that the additional acrylamide was 
associated with a shift of its parent phenyl ring away from its position in AC24, presumably to 
avoid a steric clash with D307 (of DFG), but possibly colliding with V173. Two characteristics 
distinguish AC28 from AC24 and AC25: the acrylamide functional group at the meta position, 
and the lack of a 2-methoxy substituent in aniline. These properties changed the inhibition 
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selectivity pattern significantly, eliminating their inhibitory activity against many CAMK family 
kinases, JNK kinases, and adding the binding to the pseudokinase domains of JAK1 and TYK2. 
Moreover, the cross reactivity towards MAST1 in the AGC group of AC24 and AC25 was lost in 
AC28. These clear and specific dependencies warrant further more detailed structural studies. 
AC23 and AC27 have a potential bridging water molecule in the binding pocket that could be 
an important affinity determinant. In fact, for AC27 the water in the binding pocket is the only 
apparent interaction that anchors AC27 to the hinge. The waters are unambiguous only in chain B 
(AC23) or chain D (AC27) in the electron density of the DYRK1A tetramer. Despite the missing 
electron density, a water bridging interaction may however be important, because multiple 
bridged geometries may exist. Optimization of these compounds can take this into account 
(Figure 3 and 8).   
 
 
Figure 8 Water mediated binding of AC23 (PDB: 6EIP) and AC27 (PDB: 6EIS) to DYRK1A. 
The structure of the inhibitor in the ATP pocket of DYRK1A includes a water molecule that 
enables bridging interactions between the inhibitor and the K188, E203 and D307 for AC23, and 
between the inhibitor and the hinge carbonyl of E239 and amide nitrogen of L241 for AC27. 
There is no clear electron density for a water in the other chains; however, some diffuse electron 
density suggests it to be present there also. 
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AC23 and especially AC27 were the most active compounds in the cell line assay (NFATluc, 
Figure 6). These compounds were active at lower concentrations compared to harmine. AC23 
reached a twofold activity increase at 1 µM, and AC27 reached twofold activation already at 
0.1 µM. In contrast, harmine reaches this level only at ~5 µM, i.e. AC23 and AC27 may be seen 
as 5x and 50x as active, respectively. On the other hand, both AC23 and AC27 show reduced 
activity at concentrations above 10 µM. This could be an indication that these higher 
concentrations introduce toxicity to the cells, while harmine continues to exhibit dose dependent 
inhibition at these concentrations.  
As mentioned above, several DYRK1A inhibitors were identified in the recent past, but none of 
these compounds has met the selectivity standards needed for use as probe molecules. Harmine, 
one of the most commonly used inhibitors in DYRK1A related research, has strong cross 
inhibition of monoamine oxidase that would create severe side effects. The low selectivity also 
makes harmine unsuitable as a probe to test DYRK1A inhibition in cell lines. Efforts to eliminate 
the MAO inhibition while keeping the DYRK1A inhibition lead to the harmine derivative 
AnnH7525. Another DYRK1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), was 
shown to correct cognitive deficits in Down syndrome mouse models and in humans26. However, 
it also potentially has multiple targets (and correspondingly is under consideration for use a broad 
range of disorders) and cannot be considered a DYRK specific inhibitor. The compounds 
EHT1610 and EHT5372 are among the most selective DYRK inhibitors identified so far27, 28. 
Crystal structures of these compounds in complex with a kinase are available for DYRK2 (5LXD 
and 5LXC). A comparison of this scaffold to AC27, one of the more selective compound in our 
series, shows some remarkable similarities. First, a structural comparison of the EHT1610 and 
EHT5372 compound bound to DYRK2 suggests that the canonical hinge binding may be less 
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essential for high affinity binding in DYRK28 as it is for AC27, because its hinge interaction is 
only indirect, via a bridging water molecule. Secondly, all three compounds interact with the P-
loop, and the trifluoromethyl in AC27 or the 2-fluoro- and 2-chloro-benzyl group of EHT1610 
and EHT5372 occupy the same space. One major difference is in the overall orientation of the 
inhibitors.   Considering them "U" or horse-shoe shaped, the opening of the "U" for AC27 points 
toward the P-loop aryl F160, while the orientation is reversed for the EHT inhibitors. The benzyl 
rings of AC27 and the EHT inhibitors are roughly perpendicular to each other. (Figure 9) 
 
 
Figure 9 Comparison of the binding of AC27 (light green, PDB: 6EIS) with EHT1610 (red, 
PDB: 5LXD) and EHT5372 (magenta, PDB: 5LXC); (DYRK1A, salmon; DYRK2, gray). 
 
 
 Additional inhibitors of DYRK1A discussed in the literature include a derivative of a marine 
sponge alkaloid Leucettine L41, which has shown some efficacy in mice to prevent memory 
impairment29. Benzothiazole fragments18, 30 and the independently developed benzothiazoles 
INDY23 and BINDY24  are also effective inhibitors of DYRK1A. FINDY is a selective inhibitor 
of the kinase DYRK1A that targets its folding process31. A detailed review article of the most 
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recent DYRK1A inhibitors summarizes these results22. The lead compounds we present here, 
along with their binding poses as seen in the crystal structures, represent valuable additional 





Twenty-two new compounds were tested for their ability to inhibit and bind to DYRK1A. 
These compounds belong to diverse chemical scaffolds of kinase inhibitors and their inhibitory 
strengths (Ki) vary between 200 nM and >10 µM. Kinase profiling showed that some of the 
compounds (e.g. AC12 and AC15) have a broad spectrum of kinase inhibition, while others are 
much more specific against DYRK and CLK2. These new scaffolds offer novel opportunities to 
design DYRK1A inhibitors. Their inhibitory properties vary across the characterization methods 
and the results of in vitro vs cellular assays, especially the pT212-tau phosphorylation vs. the 
NFAT Luc reporter assays, were less strongly correlated for the compounds. However, this only 
underlines the importance to study inhibitors in multiple approaches to find the most effective 
inhibitor.  Newly revealed binding features, such as the CH-O interaction with Asn292, or the 
bound waters that serve as anchors to the catalytic lysine or the hinge, may provide valuable 
information for optimization of these inhibitors against DYRK1A and related kinases, targeting 





Page 23 of 44
ACS Paragon Plus Environment


































































1. Synthesis of the inhibitors 
 
AC15
32, AC2033, AC2334, AC2735 and AC2836 were previously reported as TRK, Bcr-Abl, 
ERK5, mTOR, and HIPK2 inhibitors, respectively. AC1232  and AC2237 were synthesized 
following procedure described in references. AC24 and AC25 were generated from a common 
intermediate 1-(4-isothiocyanato-3-methoxyphenyl)-4-methylpiperazine 2, which was obtained 
from reaction of 2-methoxy-4-(4-methylpiperazin-1-yl)aniline with triphosgene under basic 
condition (Scheme 1). This isothiocyanate intermediate was allowed to react with cyanamide in 
the presence of t-BuOK, followed by addition of phenacyl bromide to give the desired 2,4-
diaminothiazoles AC24 in one-pot synthesis with 96% yield. Intermediate 3 was synthesized by 
similar procedure with 4-nitrophenacyl bromide and subjected to primary amine protection to 
generate 4. Reduction of nitro group by platinum dioxide gave rise to corresponding aniline 
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Scheme 1. Synthesis of AC24 and AC25a 
 
 
aReaction conditions: (a) 1.0 equiv of thiophosgene, 5.0 equiv of TEA, CHCl3, rt, 3 h, 94%; (b) 1) 
2.4 equiv of NH2CN,  1.5 equiv of t-BuOK, acetonitrile, 0
 oC to rt, 1 h; 2) 1.0 equiv of 2-bromo-
1-phenylethan-1-one, rt, 4 h, 96%; (c) 1) 2.4 equiv of NH2CN,  1.5 equiv of t-BuOK, acetonitrile, 
0 oC to rt, 1 h; 2) 1.0 equiv of 2-bromo-1-(4-nitrophenyl)ethan-1-one, rt, 4 h, 47%; (d) 1.0 equiv 
of (Boc)2O, 0.3 equiv of DMAP, 2.0 equiv of DIEA, CH2Cl2, rt, 2 days, 89%; (e) 1) 1.05 equiv of 
PtO2, H2, MeOH, rt, 1 h; 2) 1.27 equiv acryloyl chloride, CH2Cl2, 0 
oC, 0.5 h; 3) TFA, 0 oC to rt, 
1 h, 46%. 
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2. Chemistry.  
Unless otherwise noted, reagents and solvents were obtained from commercial suppliers and 
were used without further purification. 1H NMR and 13C NMR were recorded on Bruker Ascend 
500. 1H NMR spectra were 500 MHz, and chemical shifts are reported in parts per million 
(ppm,δ) downfield from tetramethylsilane (TMS). Coupling constants (J) are reported in Hz. 
Spin multiplicities are described as s (singlet), d (doublet), t (triplet), m (multiplet), and br 
(broad). IR spectra were recorded on a Bruker ALPHA II Platinum single reflection diamond 
ATR Module. High-resolution mass spectra (HRMS) were recorded on a Bruker Impact HD q-
TOF Mass Spectrometer. Preparative HPLC was performed on a Waters Symmetry C18 column 
(19 x 50 mm, 5 μM) using a gradient of 5-95% acetonitrile in water containing 0.05% 
trifluoroacetic acid (TFA) over 8 min (10 min run time) at a flow rate of 30 mL/min. Analytic 
HPLC was performed on a SunFire C18 column (4.6 x 150 mm, 3.5 μM) using a gradient of 5-
95% acetonitrile in water containing 0.05% trifluoroacetic acid (TFA) over 15 min (17 min run 
time) at a flow rate of 1.0 mL/min. Purities of compounds were greater than 95% unless indicated 
otherwise, as determined by analytical HPLC.  
4-[3-(Pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzene-1-sulfonamide (XMD7-117, 
AC-12). 
1H NMR (500 MHz, DMSO-d6) δ 12.47 (s, 1H), 9.36 (br, 1H), 9.08 – 8.48 (m, 4H), 8.29 
(d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.3 Hz, 2H), 7.99 – 7.77 (m, 3H), 7.43 (s, 2H). 13C NMR (126 
MHz, DMSO-d6) δ 149.5, 143.2, 143.2, 142.2, 142.5, 142.4, 138.6, 128.5, 128.1, 127.8, 126.7, 
126.6, 117.4, 110.3. IR ν max (neat): 3299, 3007, 2862, 1586, 1527, 1476, 1329, 1156, 1095, 909, 
670, 589, 544 cm-1. HRMS (ESI) m/z: calcd for C18H14N4O2S [M + H]
+, 351.0910; found 
351.0909.  
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1H NMR (500 MHz, CD3OD) δ 9.27 (d, J = 1.2 Hz, 1H), 8.84 (s, 1H), 8.70 (d, J = 4.9 Hz, 
1H), 8.47 (d, J = 7.9 Hz, 1H), 7.61 (dd, J = 7.9, 5.0 Hz, 1H), 7.10 (d, J = 2.8 Hz, 1H), 6.94 (d, J = 
8.7 Hz, 1H), 6.79 (dd, J = 8.6, 2.8 Hz, 1H), 3.83 (s, 3H). 13C NMR (126 MHz, CD3OD) δ 192.9, 
154.7, 150.8, 150.7, 150.3, 149.6, 141.0, 139.9, 138.7, 134.5, 127.6, 125.9, 123.3, 117.1, 116.9, 
113.00, 55.3. IR ν max (neat): 3424, 3252, 3124, 2836, 1632, 1585, 1503, 1222, 1207, 1032, 798, 
679, 442 cm-1. HRMS (ESI) m/z: calcd for C17H15N5O2 [M + H]
+, 322.1299; found 322.1299.  
1-(4-Isothiocyanato-3-methoxyphenyl)-4-methylpiperazine (2) To a solution of 2-methoxy-
4-(4-methylpiperazin-1-yl)aniline (1) (663 mg, 3.0 mmol) and triethylamine (2.10 mL, 15.0 
mmol) in 10 mL CHCl3 at 0 
oC, thiophosgene (0.23 mL, 3.0 mmol) was added. After 15 minutes, 
the reaction mixture was stirred at room temperature. Once the reaction completed (about 3 
hours), the reaction mixture was diluted with ethyl acetate, washed with ice water and brine. 
After the organic layer was dried with MgSO4, the solvent was removed. The crude product of 
title compound (747 mg, 94%) was used directly for next step without purification (84.9 % 
purity). 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 8.6 Hz, 1H), 6.38 – 6.26 (m, 2H), 3.81 (s, 
3H), 3.20 (t, J = 5.1 Hz, 4H), 2.56 (t, J = 5.0 Hz, 4H), 2.33 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 156.7, 151.3, 137.8, 128.8, 126.1, 107.4, 99.6, 55.9, 54.7, 48.4, 45.9. IR ν max (neat): 2936, 
2794, 2703, 2099, 1595, 1565, 1510, 1417, 1263, 1252, 1211, 1203, 1134, 1025, 1008, 969, 815, 
556 cm-1. HRMS (ESI) m/z: calcd for C13H17N3OS [M + H]
+, 264.1165; found 264.1165. HPLC: 
84.9 % at 254 nM. 
(4-Amino-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(phenyl) 
methanone (XMD14-124, AC24). To a solution of 1-(4-isothiocyanato-3-methoxyphenyl)-4-
methylpiperazine (2) (30 mg, 0.12 mmol) in 1.0 mL acetonitrile at 0 oC cyanamide (10 mg, 
0.24 mmol) was added, followed by potassium tert-butoxide (0.15 mL 1M solution in THF, 
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0.15 mmol). After 10 minutes, the reaction mixture was stirred at room temperature. Once the 
reaction completed (about one hour), 2-bromo-1-phenylethan-1-one (20 mg, 0.1 mmol) was 
added at room temperature. The reaction completed in about four hours. The reaction mixture 
was diluted with ethyl acetate, washed with ice water and brine. After the organic layer was dried 
with MgSO4, the solvent was removed and the residue was purified by column purification 
(CH2Cl2/3.5 N Ammonia in MeOH) to afford desired  compound (40.7 mg, 96%). 
1H NMR (500 
MHz, CD3OD) δ 7.56 – 7.51 (m, 2H), 7.47 (d, J = 8.7 Hz, 1H), 7.40 – 7.24 (m, 3H), 6.56 (d, J = 
2.5 Hz, 1H), 6.44 (dd, J = 8.8, 2.5 Hz, 1H), 3.75 (s, 3H), 3.18 (t, J = 5.0 Hz, 4H), 2.74 (t, J = 5.0 
Hz, 4H), 2.42 (s, 3H). 13C NMR (126 MHz, CD3OD) δ 183.8, 172.5, 167.00, 152.8, 150.1, 141.9, 
130.1, 128.0, 126.6, 124.4, 120.5, 107.6, 100.4, 94.4, 54.9, 54.2, 48.1, 44.0. IR ν max (neat): 2806, 
1602, 1537, 1213, 1350, 1262, 1241, 737, 699, 509 cm-1. HRMS (ESI) m/z: calcd for 
C22H25N5O2S [M + H]
+, 424.1802; found 424.1802.  
(4-Amino-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(4-
nitrophenyl)methanone (3). To a solution of 1-(4-isothiocyanatophenyl)-4-methylpiperazine (2) 
(157.8 mg, 0.6 mmol) in 5.0 mL acetonitrile at 0 oC cyanamide (50 mg, 1.19 mmol) was added, 
followed by potassium tert-butoxide (0.75 mL 1M solution in THF). After 10 minutes, the 
reaction mixture was stirred at room temperature. Once the reaction completed (about one hour), 
2-bromo-1-(4-nitrophenyl)ethan-1-one (122 mg, 0.5 mmol) was added at room temperature. The 
reaction completed in about four hours. The reaction mixture was diluted with ethyl acetate, 
washed with ice water and brine. After the organic layer was dried with MgSO4, the solvent was 
removed and the residue was purified by column purification (CH2Cl2/3.5 N Ammonia in MeOH) 
to afford desired compound (219 mg, 47%). 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 8.3 Hz, 
2H), 7.93 (s, 1H), 7.78 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.6 Hz, 1H), 6.49 – 6.36 (m, 2H), 3.78 (s, 
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3H), 3.13 (t, J = 5.0 Hz, 4H), 2.50 (t, J = 5.0 Hz, 4H), 2.28 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 181.5, 170.8, 165.9, 151.2, 150.2, 148.7, 147.3, 128.2, 123.7, 122.1, 119.5, 107.7, 100.0, 55.8, 
55.0, 49.1, 46.1. IR ν max (neat): 2808, 1597, 1533, 1417, 1339, 1262, 1242, 972, 735, 705, 473 
cm-1. HRMS (ESI) m/z: calcd for C22H24N6O4S [M + H]
+, 469.1653; found 469.1652. 
tert-Butyl (2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(4-nitrobenzoyl) 
thiazol-4-yl)carbamate (4). To a stirred suspension of (4-amino-2-((2-methoxy-4-(4-
methylpiperazin-1-yl)phenyl)amino) thiazol-5-yl)(4-nitrophenyl)methanone (3) (72 mg, 
0.15 mmol) in 4.0 mL dichloromethane at room temperature, 4-dimethylaminopyridine (6.0 mg, 
0.05 mmol), N,N-diisopropylethylamine (0.06 mL, 0.3 mmol), and di-tert-butyl dicarbonate 
(34 mg, 0.15 mmol) were added. After 10 minutes, the reaction mixture turned clear. When the 
reaction completed (about 2 days), the reaction mixture was concentrated and the residue was 
purified by column purification (CH2Cl2/3.5 N Ammonia in MeOH) to afford titled compound 
(93.1% purity, 77 mg, 89%). 1H NMR (500 MHz, CD3OD) δ 8.39 (d, J = 8.4 Hz, 2H), 7.99 (d, J 
= 8.4 Hz, 2H), 7.14 (d, J = 8.5 Hz, 1H), 6.77 (d, J = 2.5 Hz, 1H), 6.68 (dd, J = 8.7, 2.5 Hz, 1H), 
4.07 – 3.92 (m, 2H), 3.84 (s, 3H), 3.72 – 3.60 (m, 2H), 3.32 – 3.05 (m, 4H), 3.02 (s, 3H), 1.40 (s, 
9H). 13C NMR (126 MHz, CD3OD) δ 184.0, 167.9, 163.9, 155.4, 152.7, 151.5, 149.1, 146.8, 
129.7, 128.2, 123.4, 120.5, 107.8, 100.7, 83.9, 54.9, 53.3, 46.5, 42.2, 26.6. IR ν max (neat): 1717, 
1676, 1610, 1520, 1345, 1293, 1127, 1091, 847, 433 cm-1. HRMS (ESI) m/z: calcd for 
C27H32N6O6S [M + H]
+, 569.2177; found 569.2182. 
N-(4-(4-Amino-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)thiazole-5-
carbonyl)phenyl)acrylamide (XMD15-27, AC25). A suspension of tert-butyl (2-((2-methoxy-
4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(4-nitrobenzoyl)thiazol-4-yl)carbamate (4) (50 mg, 
0.088 mmol) and platinum dioxide (21 mg, 0.093 mmol) in 6.0 mL methanol was stirred at room 
temperature under hydrogen atmosphere. After one hour, the reaction mixture was filtered. The 
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solvent of the filtrate was removed and the residue was dried under vacuum. The crude product 
was used directly without purification. To its solution in 3.0 mL dichloromethane at 0 oC acryloyl 
chloride (9 µL, 0.11 mmol) was added. Once the reaction completed (in about 30 minutes), 1.0 
mL trifluoroacetic acid was added at 0 oC. The temperature of reaction mixture gradually 
increased to room temperature. When the reaction completed, reaction mixture was concentrated 
and the resulting residue was purified by reverse-phase prep-HPLC using a water 
(0.05%TFA)/methanol (0.05% TFA) gradient to afford the desired compound (20.5 mg, 46%). 
1H NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.86 (s, 1H), 7.71 (t, J = 9.8, 8.3 Hz, 2H), 7.59 
(d, J = 8.3 Hz, 2H), 7.41 (s, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.51 - 6.41 (m, 2H), 6.28 (dd, J = 17.0, 
2.0 Hz, 1H), 5.79 (dd, J = 10.0, 1.9 Hz, 1H), 3.79 (s, 3H), 3.17 (t, J = 4.9 Hz, 4H), 2.45 (t, J = 5.0 
Hz, 4H), 2.23 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 181.8, 166.7, 163.8, 141.1, 137.5, 
132.2, 128.1, 127.8, 119.1, 107.25, 100.3, 92.9, 56.0, 55.1, 48.5, 46.2. IR ν max (neat): 2920, 
2849, 1672, 1594, 1517, 1409, 968, 762, 727 cm-1. HRMS (ESI) m/z: calcd for C25H28N6O3S [M 
+ H]+, 493.2016; found 493.2016.  
 
3. Expression and purification 
A DYRK1A construct comprising the kinase domain (126-490) was cloned into pEXP17 with 
N-terminal 6x(HIS) affinity tags and TEV protease cleavage sites17, 18. Expression was done in 
shaker flask cultures overnight at 17.8 °C in TB media. For the purification of DYRK1A the cells 
were resuspended in a lysis buffer containing 50 mM sodium phosphate buffer pH 8.0 with 500 
mM NaCl and of 0.5% Tween20. Purification was done via NiNTA columns and an imidazole 
gradient (10-500 mM), followed by a TEV cleavage overnight and a second NiNTA to separate 
the kinase from uncut protein and the protease. Final purification for DYRK1A was done via size 
exclusion chromatography (SEC buffer: 50 mM MOPS pH 6.8, 50 mM KCl, 2 mM β-Me). 
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4. Crystallization  
DYRK1A was concentrated to 7-10 mg/mL in SEC buffer and mixed with inhibitor solutions 
in DMSO to achieve approximately a 5-10 fold excess of inhibitor. The final concentration of 
DMSO was ~5%. The protein/inhibitor mixture was than mixed 1:1 with the crystallization 
solution (100 mM KSCN, 50-100 mM LiCl (or NaCl, or KCl), 10-20% PEG3350) for a final 
drop size of 4 µl. Crystallization was done in 24 well hanging drop plates. Octahedron shaped 
crystals appeared within 1-7 days at room temperature. Crystals were cryo-protected with 30% 
ethylene glycol and flash frozen in liquid nitrogen.  
 
5. Structure solving and refinement 
Crystals were measured at the ESRF Grenoble, France. The images were integrated using the 
software XDSapp38. The structure was solved by molecular replacement using the DYRK1A 
structure 5A4T as a search model. Refinement was done by Phenix39 and the CCP440 program 
Refmac541. The waters were placed by the program Coot 0.7.242.  The crystallographic data and 
model statistics are summarized in Table S2. 
 
6. Activity assay  
The determination of the IC50 constants for DYRK1A was done by an ATP regenerative 
NADH consuming assay16. The enzyme velocity was measured at 340 nm over a time period of 
300 s at room temperature. ATP and the peptide RRRFRPASPLRGPPK (DYRKtide) were used 
as substrates. The reaction mixture was composed of 75 µl of 100 mM MOPS buffer pH 6.8, 10 
mM KCl, 10 mM MgCl, 1 mM phosphoenolpyruvate, 1 mM DYRKtide, 1 mM β-ME, 
15 units/mL lactate dehydrogenase, 10 units/ml pyruvate kinase and 10.7 mM NADH.  10 µl of 
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~5-20 µM DYRK1A, 2 µL of inhibitor in DMSO in concentrations ranging from 4 nM and 20 
µM and 10 µL of ATP 128 µM were added to a total volume of 97 µL. All measurements were 
done in triplicate at room temperature. All other in vitro kinase assays were conducted using the 
SelectScreen Kinase Profiling Service at Thermo Fisher Scientific (Madison, WI). The protocols 
are available from Thermo Fisher Scientific website. 
 
7. Cell culture, transfections and treatments 
DNA constructs: The plasmid encoding EGFP-tagged DYRK1A has been described earlier43 
and was a kind gift from Dr. D'Arcangelo (Rutgers, USA). The expression vector encoding the 
FLAG-tagged tau44 was a kind gift from Dr. Paudel (McGill University, Canada). 
NCI-H1299 cells (ATCC-CRL-5803) were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum (Invitrogen), 2 mM L-glutamine, penicillin 
(100 U/mL), and streptomycin (100 µg/mL). Lipofectamine LTX (Life Technologies) reagent 
was used to transfect the cells according to the manufacturer’s instructions. The cells were treated 
for 2 hours with the indicated concentration of compound the day after transfection before they 
were harvested in MKK-lysis buffer (50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% 
(w/v) Triton-X 100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate and 0.27 M sucrose) and processed for immunoblotting. 
 
8. Immunoblotting 
For detection of ectopically expressed FLAG-TAU or EGFP-DYRK1A, the samples were 
analyzed by SDS-PAGE (4–12% NUPAGE, Life Technologies), transferred to a nitrocellulose 
membrane (Li-Cor) and probed with a rabbit anti- Phospho-tau-T212 (1:1000) antibody or a 
mouse monoclonal anti-FLAG antibody. Detection and quantification were performed either 
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directly using anti-GFP Dylight 800-conjugated antibody or IRDye 800CW-conjugated goat anti-
rabbit IgG (H&L) (1:10000) or IRDye 680LT-conjugated donkey anti-mouse IgG (H&L) 
(1:10000) and the Odyssey Infrared Imaging System (Li-Cor Biosciences). Protein molecular 
mass was estimated using the MagicMark Western protein standard (Life technologies). 
 
9. Antibodies 
The polyclonal antibody against tau phosphorylated at threonine 212 (44-740G) was purchased 
from (Life Technologies). The monoclonal antibody against FLAG (F1804) was purchased from 
Sigma-Aldrich. The anti-GFP Dylight 800-conjugated antibody (600-145-215) was purchased 
from Rockland. The IRDye 800CW-conjugated goat anti-rabbit IgG (H&L) and IRDye 680LT-
conjugated donkey anti-mouse IgG (H&L) were purchased from Li-Cor Bioscience. 
 
10. Generation of DYRK1A-NFAT-luc reporter cell line. 
The pDEST-LTR-EGFP, a mammalian transfection vector for stable and doxycycline 
controlled inducible expression of N-terminal-EGFP tagged fusion constructs under the control 
of a truncated CMV promoter, was a kind gift from Dr. Trond Lamark UiT, Tromsø, Norway45. 
The cDNA encoding human DYRK1A was amplified from the IMAGE clone; 
IMAGE:100061742 with the following primers: 
 5-CACCATGCATACAGGAGGAGAGACTTCAGC-3` and 
5-TCACGAGCTAGCTACAGGACTCTG-3,  
cloned into the pENTR using the pENTR topo cloning kit (Thermo Fischer Scientific). The final 
pENTR-DYRK1a construct was verified by DNA sequencing. The DYRK1A was transferred 
from the pENTR-DYRK1A to the vector pDEST-LTR-EGFP to generate the retroviral 
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expression vector pEXP-LRT-EGFP-DYRK1A using the Gateway LR reaction (Thermo Fischer 
Scientific).   
 
Phoenix HEK cells were transfected with the pEXP-LRT-EGFP-DYRK1A plasmid using 
TransIT-LT1 transfection agent (Mirus Bio LLC) following the manufacturer´s protocol. Forty-
eight and seventy-two hours later the supernatant were collected and filtered through a 0.45 µm 
filter. The supernatant was  supplemented with 5 µg/mL proteome sulphate and used to transduce 
the NFAT / LUCPorter™ Stable Reporter HEK Cell Line (Novus Biologicals), which contains 
express a stable renilla reporter gene under control of a NFAT response element. Two day after 
the transduction the cell were reseeded in medium containing 5µg/mL blasticidine and 
blasticidine resistant pools of cells were propagated and tested for expression of EGFP-DYRK1 
fusion protein in absence and presence of 1 µg/ml doxycycline. (Supporting information) 
 
11. Kinome Profiling.  
Kinome profiling was performed using KinomeScan ScanMAX at compound concentration of 
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Supporting information available: Complete table with all 23 inhibitors, molecular formula 
strings of the inhibitors, scaffolds of all 23 inhibitors. Crystallographic table of the nine crystal 
structures, omit maps, surface plots and a superimposition of all the nine inhibitors bound to the 
ATP pocket of DYRK1A. Table of the kinome scan. Additional tau phosphorylation assays. 
Overview of the cell based NFAT mediated luciferase reporter gene activity assay including the 
positive controls. NMR spectra of the compounds. 
Accession Codes 
PDB codes for DYRK1A complexes: compound AC12, 6EIF; compound AC15, 6EJ4; 
compound AC20, 6EIJ; compound AC22, 6EIL; compound AC23, 6EIP; compound AC24, 
6EIQ; compound AC25, 6EIR; compound AC27, 6EIS; compound AC28, 6EIV.  
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